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Anifrolumab, an Anti–Interferon-a Receptor
Monoclonal Antibody, in Moderate-to-Severe
Systemic Lupus Erythematosus
Richard Furie,1 Munther Khamashta,2 Joan T. Merrill,3 Victoria P. Werth,4 Kenneth Kalunian,5
Philip Brohawn,6 Gabor G. Illei,6 Jorn Drappa,6 Liangwei Wang,6 and Stephen Yoo,7
for the CD1013 Study Investigators
Objective. To assess the efficacy and safety of
anifrolumab, a type I interferon (IFN) receptor antagonist,
in a phase IIb, randomized, double-blind, placebo-
controlled study of adults with moderate-to-severe systemic
lupus erythematosus (SLE).
Methods. Patients (n5 305) were randomized to
receive intravenous anifrolumab (300 mg or 1,000 mg) or
placebo, in addition to standard therapy, every 4 weeks for
48 weeks. Randomization was stratified by SLE Disease
Activity Index 2000 score (<10 or‡10), oral corticosteroid
dosage (<10 or ‡10 mg/day), and type I IFN gene signa-
ture test status (high or low) based on a 4-gene expression
assay. The primary end point was the percentage of
patients achieving an SLE Responder Index (SRI[4])
response at week 24 with sustained reduction of oral cor-
ticosteroids (<10 mg/day and less than or equal to the
dose at week 1 from week 12 through 24). Other end
points (including SRI[4], British Isles Lupus Assessment
Group [BILAG]–based Composite Lupus Assessment
[BICLA], modified SRI[6], and major clinical response)
were assessed at week 52. The primary end point was ana-
lyzed in the modified intent-to-treat (ITT) population and
type I IFN–high subpopulation. The study result was con-
sidered positive if the primary end point was met in either
of the 2 study populations. The Type I error rate was con-
trolled at 0.10 (2-sided), within each of the 2 study popu-
lations for the primary end point analysis.
Results. The primary end point was met by more
patients treated with anifrolumab (34.3% of 99 for 300 mg
and 28.8% of 104 for 1,000 mg) than placebo (17.6% of 102)
(P5 0.014 for 300 mg and P5 0.063 for 1,000 mg, versus
placebo), with greater effect size in patients with a high
IFN signature at baseline (13.2% in placebo-treated
patients versus 36.0% [P5 0.004] and 28.2% [P5 0.029])
in patients treated with anifrolumab 300 mg and 1,000
mg, respectively. At week 52, patients treated with
anifrolumab achieved greater responses in SRI(4)
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(40.2% versus 62.6% [P< 0.001] and 53.8% [P5 0.043]
with placebo, anifrolumab 300 mg, and anifrolumab 1,000
mg, respectively), BICLA (25.7% versus 53.5% [P< 0.001]
and 41.2% [P5 0.018], respectively), modified SRI(6)
(28.4% versus 49.5% [P5 0.002] and 44.7% [P5 0.015],
respectively), major clinical response (BILAG 2004 C or
better in all organ domains from week 24 through week
52) (6.9% versus 19.2% [P5 0.012] and 17.3% [P5 0.025],
respectively), and several other global and organ-specific
end points. Herpes zoster was more frequent in the
anifrolumab-treated patients (2.0% with placebo treat-
ment versus 5.1% and 9.5% with anifrolumab 300 mg
and 1,000 mg, respectively), as were cases reported as
influenza (2.0% versus 6.1% and 7.6%, respectively), in
the anifrolumab treatment groups. Incidence of serious
adverse events was similar between groups (18.8% ver-
sus 16.2% and 17.1%, respectively).
Conclusion. Anifrolumab substantially reduced
disease activity compared with placebo across multiple
clinical end points in the patients with moderate-to-
severe SLE.
Systemic lupus erythematosus (SLE) is a multi-
system autoimmune disease (1) leading to significant
morbidity and shortened lifespan (2–4). Treatment of
SLE is challenging because of the limited efficacy and
poor tolerability of standard therapy (5–7).
Evidence supports activation of the type I inter-
feron (IFN) system as a central pathogenic mediator in
SLE (8–11). Cell signaling by all type I IFNs, including
IFNa, IFNb, IFNE, IFNk, and IFNv, is mediated by the
type I IFN-a/b/v receptor (IFNAR), resulting in IFN-
stimulated gene transcription, otherwise known as the
IFN gene signature (12). Consequently, blockade of
IFNAR may reverse some of the immune dysregulation
that occurs in SLE (13,14).
Results of recent phase II clinical studies of anti-
IFNa antibodies have been mixed. Rontalizumab did not
meet the primary or secondary end points in a recent
study (15). However, a post hoc analysis suggested poten-
tial benefit in a small subset of patients with a low baseline
IFN signature. In contrast, sifalimumab met primary and
some secondary end points (16), but the treatment effects
were modest. Both of these molecules have specificity
only for IFNa, leaving other type I IFNs unaffected and
able to bind IFNAR.
Anifrolumab is a fully human, IgG1k monoclonal
antibody that binds to IFNAR and prevents signaling by
all type I IFNs (17). Anifrolumab exhibited a favorable
safety profile and sustained inhibition of the type I IFN
gene signature in a phase I study of patients with
scleroderma (18). Given the similarities in type I IFN
activity in SLE and scleroderma (19) the present phase
IIb study was conducted to evaluate the efficacy and
safety of 2 fixed intravenous dosages of anifrolumab in
adults with moderately to severely active SLE with inade-
quate responses to standard therapy.
PATIENTS AND METHODS
Patients. This study included patients ages 18–65 years
with SLE. Patients had to weigh $40 kg and fulfill $4 of the 11
American College of Rheumatology 1997 classification criteria for
SLE (20,21). At screening, all patients were required to have anti-
nuclear antibodies and/or anti–double-stranded DNA (anti-
dsDNA) antibodies, and/or anti-Sm antibodies, and to be receiving
treatment with at least one of the following: oral prednisone
(#40 mg/day or equivalent), azathioprine (#200 mg/day), an anti-
malarial, mycophenolate mofetil/mycophenolic acid (#2.0 gm/
day), ormethotrexate (#25mg/week).
Treatments for SLE had to be administered for at least
24 weeks prior to study entry and at stable dosages for $2
weeks (for prednisone and nonsteroidal antiinflammatory drugs)
or $8 weeks (for other therapies) before screening. Biologic
agents and protocol-prohibited immunosuppressants had to be
discontinued before the study.
Patients had to meet all of the following disease activity
criteria at screening: a score of $6 on the SLE Disease Activity
Index 2000 (SLEDAI-2K) (22), excluding points attributable to
lupus headache or organic brain syndrome; a British Isles Lupus
Assessment Group (BILAG) 2004 (23) organ domain score of
$1A or$2B (24); and a physician’s global assessment of disease
activity of$1 on a visual analog scale from 0 (none) to 3 (severe
disease). In addition, patients were required to have a score
of $4 in clinical components of the SLEDAI-2K (clinical
SLEDAI-2K; points attributed to laboratory components were
excluded) at week 1 (prior to receiving the study drug). Patients
with active and severe lupus nephritis or neuropsychiatric SLE
were excluded from the study. Additional study exclusion criteria
are provided in the Supplementary Methods, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.39962/abstract.
Study design. This randomized, double-blind, placebo-
controlled, parallel-group phase IIb study (A Phase II, Random-
ized Study to Evaluate the Efficacy and Safety of MEDI-546
in Subjects with Systemic Lupus Erythematosus [MUSE];
ClinicalTrials.gov identifier: NCT01438489) was conducted at 101
sites in 15 countries (see Supplementary Methods, available on
the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.39962/abstract). Patients were randomized
1:1:1 to receive intravenous infusions of placebo, anifrolumab
300 mg, or anifrolumab 1,000 mg. Treatment was administered
every 4 weeks with the final dose administered at week 48. The
primary and secondary efficacy measures were assessed at week
24 and week 52, respectively. All patients were required to com-
plete a 12-week follow-up period after administration of the final
dose of the study drug. During the treatment period, there were
13 scheduled monthly visits. The follow-up period consisted of 3
visits, conducted 4, 8, and 12 weeks after the last dose. Randomi-
zation was stratified by type I IFN gene signature (IFN high or
IFN low), dosage of oral corticosteroids (,10 mg/day or$10 mg/
day of prednisone or equivalent), and SLEDAI-2K score (,10 or
$10) at screening. IFN gene signature was determined at a
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central laboratory using an analytically validated 4-gene (IFI27,
IFI44, IFI44L, and RSAD2) quantitative polymerase chain reac-
tion (PCR)–based test from patients’ whole blood (25).
A predetermined, DCt-based cutoff point, in the trough of the
bimodal distribution, was used to segregate patients with a high
IFN gene signature from patients with a low IFN gene signature
at baseline.
Tapering of oral corticosteroids was encouraged but was
at the discretion of the investigators. Tapering was allowed after
randomization except within 8 weeks of the primary (week 24)
and secondary (week 52) end point assessments. A maximum of
2 oral corticosteroid bursts for increased SLE disease activity
were allowed during the study. Patients with increased SLE dis-
ease activity could receive an oral corticosteroid burst between
week 1 and week 10 (increase of #40 mg/day prednisone or
equivalent), which had to be tapered to the week 1 dosage within
2 weeks of initiation of the burst; alternatively, a single intramus-
cular dose of methylprednisone (80 or 160 mg or equivalent) was
permitted. The course of oral corticosteroid burst could not
extend beyond week 10. Patients could receive an additional
oral corticosteroid burst for increased SLE disease activity
between week 24 and week 40 (increase of #20 mg/day predni-
sone or equivalent), which had to be tapered to the week 24
dosage within 2 weeks of initiation; alternatively, a single intra-
muscular dose of methylprednisone (80 mg or equivalent) was
permitted. The course of oral corticosteroids could not extend
beyond week 40.
This study was conducted in accordance with the prin-
ciples of the Declaration of Helsinki and the International
Conference on Harmonisation Guidelines for Good Clinical
Practice. Independent ethics committee or independent insti-
tutional review board approvals were obtained, and all patients
provided written informed consent in accordance with local
requirements.
An independent data safety and monitoring board was
appointed for the study. Screening assessments of SLE organ
system involvement and disease activity requirements were
confirmed by an independent external adjudication group that
also approved patient randomization and monitored study
assessments.
Efficacy and safety evaluations. The primary efficacy
end point was a composite of the SLE Responder Index (SRI[4])
(26) at week 24 with a sustained reduction in oral corticosteroids
from week 12 through week 24 (,10 mg/day and less than or
equal to the dose received at week 1). SRI(4) response is defined
as a $4-point reduction in SLEDAI-2K score; no new BILAG
2004 A or.1 new BILAG 2004 B domain scores; and,0.3-point
deterioration in physician’s global assessment.
Secondary efficacy measures included the SRI(4)
response rates at week 52 with a sustained oral corticosteroid
reduction from week 40 through week 52 and reduction of oral
corticosteroid dosage at week 52 to #7.5 mg/day in patients who
were receiving $10 mg/day at baseline. Other efficacy measures
included percentages of patients with $50% improvement in
Cutaneous Lupus Erythematosus Disease Area and Severity
Index (CLASI) (27,28) for patients with at least moderate skin
involvement (CLASI $10); $50% improvement in swollen and
tender joint count (28 joints assessed) for patients with$8 swol-
len and $8 tender joints at baseline; response in BILAG-based
Composite Lupus Assessment (BICLA) (29); modified SRIs
requiring SLEDAI-2K reductions of 5–8 points to be considered
a responder; physician’s global assessment; proportion of
subjects with a SLEDAI-2K score of #2; proportion of subjects
with a SLEDAI-2K score of 0; clinical SLEDAI; major clinical
response defined as BILAG 2004 score of C or better in all
organ domains at week 24 with maintenance of this response
through week 52; .3-point improvement in Functional Assess-
ment of Chronic Illness Therapy–Fatigue (FACIT-F) (30);
Short Form 36 (SF-36) health survey; anti-dsDNA; and C3 and
C4 complement concentrations.
To ensure that evaluation of SLE disease activity was
consistent across study sites, training and certification was pro-
vided to investigators and designated site personnel, as appro-
priate, who were responsible for completing the following
disease evaluation assessments: SLEDAI-2K, BILAG 2004,
physician’s global assessment, CLASI, and swollen and tender
joint count evaluation. Where possible, evaluation of each
patient was performed by a single assessor. Independent
expert adjudication was undertaken throughout the study.
Safety end points included adverse events, adverse events of
special interest, laboratory assessments, and vital signs.
Statistical analysis. Analysis of the primary end point
compared response rates at week 24 between each anifrolumab
group and placebo using a logistic regression model adjusted for
randomization stratification factors. The secondary end points
and other binary end points were analyzed using the same
approach as for the primary end point. Continuous end points
were analyzed using an analysis of covariance model adjusted
for randomization stratification factors, with the relevant base-
line value as the covariate. For responder analyses, patients who
were withdrawn from treatment, had increased use of oral cor-
ticosteroids beyond the protocol-permitted dosage, or had initia-
tion of or an increase in dosage of immunosuppressant treatment
any time after baseline were defined as nonresponders.
The primary end point was analyzed in the modified
intent-to-treat (ITT) population (all randomized patients
who received any dose of study drug and had baseline primary
efficacy measurements) and a modified ITT subpopulation of
patients with a high IFN gene signature at screening (IFN-high
subpopulation). The study result was considered positive if the
primary end point was met in either of the 2 study populations.
The Type I error rate was controlled at 0.10 (2-sided),
within each of the 2 study populations (modified ITT popula-
tion and IFN-high subpopulation) for the primary end point
analysis, by performing a Cochran-Armitage trend test of all
treatment groups prior to performing pairwise comparisons
between each anifrolumab group and placebo. No multiplicity
adjustment for the 2 study populations or other end points was
applied.
The target sample size of 100 patients per group was
based on providing 88% power at the 0.10 alpha level to detect
at least 20% absolute improvement in SRI(4) response rate at
week 24 for anifrolumab relative to placebo, assuming a 40%
placebo response rate. All data analyses were conducted using
the SAS system (SAS Institute).
RESULTS
Study population. Between January 2012 and
January 2014, 626 patients were screened, with 307
randomized to receive treatment (see Supplementary
Figure 1, available on the Arthritis & Rheumatology web
site at http://onlinelibrary.wiley.com/doi/10.1002/art.399
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62/abstract). One patient in the anifrolumab 300-mg
group had poor peripheral venous access, and 1 patient
in the placebo group had an entry criteria violation and
did not receive study treatment. The modified ITT
population therefore consisted of 305 patients (102
receiving placebo, 99 receiving anifrolumab 300 mg,
and 104 receiving anifrolumab 1,000 mg). One patient
randomized to the placebo group mistakenly received a
single dose of anifrolumab (1,000-mg). This was classi-
fied as a protocol deviation. The patient was included
in the placebo group of the modified ITT population
for the efficacy analyses, but in the anifrolumab 1,000-
mg group of the safety population for the safety analyses.
Baseline characteristics (Table 1) were similar between
groups, with the following exceptions: disease duration was
shorter for the placebo group than for the anifrolumab
groups (mean 90.6 months versus 95.9 months and 100.1
months), and fewer patients in the placebo group were
receiving methotrexate (15.7% versus 19.2% and 24.0%).
The anifrolumab 1,000-mg group had a greater percentage
of white patients than the anifrolumab 300-mg and placebo
groups (49.0% versus 35.4% and 40.2%, respectively).
Efficacy. Based on the mechanism of action of
anifrolumab, the primary end point (SRI[4] response
Table 1. Demographic and baseline clinical characteristics of the patients with SLE (modified ITT
population)*
Placebo
(n5 102)
Anifrolumab
300 mg (n5 99)
Anifrolumab
1,000 mg (n5 104)
Age, years 39.36 12.9 39.16 11.9 40.86 11.6
Sex, no. (%) female 93 (91.2) 93 (93.9) 99 (95.2)
Weight, kg 68.16 19.1 69.56 17.2 70.76 17.3
Height, cm 161.26 8.1 161.66 8.5 161.96 6.7
Race, no. (%)
White 41 (40.2) 35 (35.4) 51 (49.0)
African American 12 (11.8) 19 (19.2) 10 (9.6)
Asian 13 (12.7) 3 (3.0) 6 (5.8)
American Indian/Alaska Native 0 (0.0) 4 (4.0) 1 (1.0)
Other 36 (35.3) 38 (38.4) 36 (34.6)
Ethnicity, no. (%) non-Hispanic 60 (58.8) 53 (53.5) 64 (61.5)
Disease duration, months† 90.66 86.3 95.96 76.8 100.16 90.3
High IFN gene signature, no. (%) 76 (74.5) 75 (75.8) 78 (75.0)
SLEDAI-2K global score 11.16 4.4 10.76 3.7 10.96 4.1
BILAG 2004 global score 19.86 5.8 19.66 5.8 18.66 5.7
Physician’s global assessment 1.776 0.44 1.866 0.39 1.866 0.39
CLASI activity score 6.76 5.1 7.56 6.3 7.16 6.2
Swollen joint count‡ 8.36 6.4 8.66 6.0 8.36 6.4
Tender joint count‡ 10.56 7.4 12.26 7.1 11.66 7.8
Low complement concentrations, no. (%)
C3 43 (42.2) 28 (28.3) 48 (46.2)
C4 25 (24.5) 21 (21.2) 28 (26.9)
Elevated anti-dsDNA, no. (%)§
Multiplex assay 27 (26.5) 24 (24.2) 28 (26.9)
Farr assay¶ 66 (80.5) 56 (72.7) 63 (76.8)
Concomitant immunomodulatory medications
Corticosteroids
No. (%) 88 (86.3) 79 (79.8) 91 (87.5)
Dosage, mg/day 12.86 8.1 11.36 6.4 12.56 7.8
Antimalarials, no. (%) 75 (73.5) 76 (76.8) 68 (65.4)
Corticosteroids and antimalarials, no. (%) 63 (61.8) 59 (59.6) 56 (53.8)
Azathioprine, no. (%) 19 (18.6) 23 (23.2) 21 (20.2)
Methotrexate, no. (%) 16 (15.7) 19 (19.2) 25 (24.0)
Mycophenolate, no. (%) 11 (10.8) 11 (11.1) 11 (10.6)
* Except where indicated otherwise, values are the mean6 SD. Treatment was given every 4 weeks
from week 1 to week 48. SLE5 systemic lupus erythematosus; ITT5 intent-to-treat; IFN5 interferon;
BILAG 20045British Isles Lupus Assessment Group 2004; CLASI5Cutaneous Lupus Erythematosus
Disease Area and Severity Index; anti-dsDNA5 anti–double-stranded DNA.
† From diagnosis to study entry.
‡ Based on the assessment of 28 joints.
§ The multiplex assay, an AtheNA Multi-Lyte ANA-II Plus test system, was used for screening and to
calculate Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores throughout
the study. The differences between the multiplex and Farr assays were due to a low sensitivity cutoff
point of the multiplex assay (Farr assay $5 IU/ml; multiplex assay $100 IU/ml) (32).
¶ Data were available for 82 patients receiving placebo, 77 patients receiving anifrolumab 300 mg, and
82 patients receiving anifrolumab 1,000 mg.
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with sustained reduction of oral corticosteroids at week
24) was analyzed in the overall modified ITT population
and the IFN-high subpopulation. The predefined statis-
tical significance level was 0.1; therefore, P values less
than 0.1 were considered significant for the analyses of
the primary end point. Multiplicity of comparing 2
active dosages with placebo within each study popula-
tion was adjusted by performing a Cochran-Armitage
trend test of all treatment groups prior to performing
pairwise comparisons between each anifrolumab group
and placebo. No multiplicity adjustment for the 2 study
populations was applied. The Cochran-Armitage trend
Table 2. Summary of efficacy results for patients with SLE treated with placebo or anifrolumab*
Placebo
(n5 102)
Anifrolumab
300 mg
(n5 99)
Anifrolumab 300 mg
versus placebo
Anifrolumab
1,000 mg
(n5 104)
Anifrolumab 1,000 mg
versus placebo
OR
(90% CI)† P†
OR
(90% CI)† P†
Week 24
SRI(4) (including oral corticosteroid taper) 18/102 (17.6) 34 (34.3) 2.38 (1.33–4.26) 0.014 30/104 (28.8) 1.94 (1.08–3.49) 0.063
High IFN gene signature 10/76 (13.2) 27/75 (36.0) 3.55 (1.72–7.32) 0.004 22/78 (28.2) 2.65 (1.27–5.53) 0.029
Low IFN gene signature 8/26 (30.8) 7/24 (29.2) 0.96 (0.34–2.74) 0.946 8/26 (30.8) 1.04 (0.37–2.88) 0.953
SRI(4) (excluding oral corticosteroid taper) 41/102 (40.2) 53/99 (53.5) 1.77 (1.10–2.84) 0.047 59/104 (56.7) 1.98 (1.24–3.16) 0.016
High IFN gene signature 29/76 (38.2) 41/75 (54.7) 2.03 (1.17–3.52) 0.034 47/78 (60.3) 2.50 (1.45–4.32) 0.006
Low IFN gene signature 12/26 (46.2) 12/24 (50.0) 1.13 (0.44–2.93) 0.832 12/26 (46.2) 0.96 (0.38–2.44) 0.943
Week 52
SRI(4) (including oral corticosteroid taper) 26/102 (25.5) 51/99 (51.5) 3.08 (1.86–5.09) ,0.001 40/104 (38.5) 1.84 (1.11–3.04) 0.048
High IFN gene signature 15/76 (19.7) 39/75 (52.0) 4.30 (2.34–7.91) ,0.001 30/78 (38.5) 2.52 (1.37–4.64) 0.013
Low IFN gene signature 11/26 (42.3) 12/24 (50.0) 1.47 (0.55–3.93) 0.514 10/26 (38.5) 0.89 (0.34–2.35) 0.849
SRI(4) (excluding oral corticosteroid taper) 41/102 (40.2) 62/99 (62.6) 2.66 (1.64–4.31) ,0.001 56/104 (53.8) 1.78 (1.11–2.85) 0.043
High IFN gene signature 27/76 (35.5) 45/75 (60.0) 2.98 (1.69–5.24) 0.001 43/78 (55.1) 2.33 (1.34–4.04) 0.012
Low IFN gene signature 14/26 (53.8) 17/24 (70.8) 2.07 (0.77–5.53) 0.225 13/26 (50.0) 0.85 (0.34–2.12) 0.765
Meeting oral corticosteroid taper criteria‡ 17/64 (26.6) 31/55 (56.4) 3.59 (1.87–6.89) 0.001 20/63 (31.7) 1.23 (0.64–2.37) 0.595
$50% improvement in CLASI§ 8/26 (30.8) 17/27 (63.0) 4.49 (1.67–12.12) 0.013 14/24 (58.3) 2.97 (1.08–8.19) 0.077
$50% improvement in joint counts¶ 18/37 (48.6) 32/46 (69.6) 2.67 (1.23–5.82) 0.038 31/48 (64.6) 1.92 (0.90–4.09) 0.156
BICLA responder# 26/101 (25.7) 53/99 (53.5) 3.42 (2.06–5.68) ,0.001 42/102 (41.2) 2.06 (1.25–3.42) 0.018
Modified SRI(5) 30/102 (29.4) 49/99 (49.5) 2.47 (1.51–4.06) 0.003 48/103 (46.6) 2.14 (1.31–3.49) 0.010
Modified SRI(6) 29/102 (28.4) 49/99 (49.5) 2.58 (1.57–4.23) 0.002 46/103 (44.7) 2.07 (1.27–3.37) 0.015
Modified SRI(7) 16/93 (17.2) 33/90 (36.7) 2.83 (1.58–5.07) 0.003 26/95 (27.4) 1.83 (1.01–3.32) 0.094
Modified SRI(8) 16/92 (17.4) 32/90 (35.6) 2.67 (1.49–4.80) 0.006 26/95 (27.4) 1.82 (1.00–3.29) 0.099
Physician’s global assessment decrease** 55/102 (53.9) 74/99 (74.7) 2.81 (1.67–4.71) 0.001 63/104 (60.6) 1.37 (0.85–2.20) 0.281
Clinical SLEDAI†† 44/102 (43.1) 62/99 (62.6) 2.35 (1.45–3.81) 0.004 54/104 (51.9) 1.46 (0.91–2.32) 0.185
SLEDAI #2 18/102 (17.6) 35/99 (35.4) 2.68 (1.53–4.70) 0.004 34/104 (32.7) 2.35 (1.34–4.11) 0.012
SLEDAI5 0 8/102 (7.8) 18/99 (18.2) 2.66 (1.25–5.64) 0.033 20/104 (19.2) 2.90 (1.38–6.08) 0.018
Major clinical response‡‡ 7/102 (6.9) 19/99 (19.2) 3.24 (1.49–7.04) 0.012 18/104 (17.3) 2.88 (1.32–6.26) 0.025
Disease flares
BILAG A or 2B 17/102 (16.7) 12/99 (12.1) 0.71 (0.36–1.42) 0.421 12/104 (11.5) 0.68 (0.34–1.36) 0.359
BILAG A 17/102 (16.7) 9/99 (9.1) 0.51 (0.24–1.07) 0.134 11/104 (10.6) 0.61 (0.30–1.24) 0.253
Fatigue§§ 34/98 (34.7) 41/96 (42.7) 1.46 (0.89–2.38) 0.207 43/104 (41.3) 1.35 (0.83–2.18) 0.308
SF-36
MCS¶¶ 27/102 (26.5) 36/99 (36.4) 1.68 (1.00–2.79) 0.097 35/104 (33.7) 1.44 (0.86–2.39) 0.240
PCS## 40/102 (39.2) 48/99 (48.5) 1.51 (0.94–2.44) 0.154 43/104 (41.3) 1.11 (0.69–1.78) 0.726
* Values are the number of patients/number assessed (%). Treatment was given every 4 weeks from week 1 to week 48. The observed response rates of
each treatment group are shown. SLE5 systemic lupus erythematosus; SRI5 SLE Responder Index; IFN5 interferon; BICLA5British Isles Lupus
Assessment Group (BILAG)–based Combined Lupus Assessment; SRI(5)5 SRI requiring SLE Disease Activity Index 2000 (SLEDAI-2K) reductions of
5 points; SF-365 Short Form 36; MCS5mental component summary; PCS5 physical component summary.
† Odds ratio (ORs), 90% confidence intervals (90% CIs), and nominal P values are from a logistic regression model for comparisons of each
anifrolumab group versus placebo adjusted for randomization stratification factors.
‡ Reduction of oral corticosteroid dosage to #7.5 mg/day in patients who were receiving $10 mg/day at baseline.
§ $50% decrease in the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score in patients who had a score
of $10 at baseline.
¶ $50% decrease in the swollen and tender joint count from baseline in patients with $8 swollen and $8 tender joints at baseline.
# Reduction of baseline BILAG 2004 index A to B/C/D and B to C/D, no BILAG 2004 index worsening in other organ domains (no new
BILAG score of A or B), increase in total SLEDAI-2K of ,1, and increase in the physician’s global assessment of ,0.3.
** $0.3-point improvement from baseline.
†† $4-point reduction in clinical components (no laboratory components) of the SLEDAI.
‡‡ BILAG 2004 score of C or better in all organ domains at week 24 with maintenance of this response through week 52.
§§ .3-point improvement from baseline in Functional Assessment of Chronic Illness Therapy–Fatigue score.
¶¶ $3.8-point improvement from baseline.
## $3.1-point improvement from baseline.
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test of all treatment groups showed that the number of
patients in whom the primary end point was achieved
was greater for anifrolumab versus placebo in the modi-
fied ITT population (P5 0.072) and in the IFN-high
subpopulation, which included 75% of the patients
(P5 0.034). In pairwise comparisons, both anifrolumab
groups had greater response rates compared with pla-
cebo (17.6%). A response was achieved in 34.3% of the
patients treated with anifrolumab 300 mg (P5 0.014
versus placebo) and in 28.8% of the patients treated
with anifrolumab 1,000 mg (P5 0.063 versus placebo).
The response rates in the IFN-high subpopulation were
13.2% for the placebo group, 36.0% for the anifrolumab
300-mg group (P5 0.004 versus placebo), and 28.2% for
the anifrolumab 1,000-mg group (P5 0.029 versus pla-
cebo) (see Supplementary Figure 2, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39962/abstract).
At week 52, anifrolumab treatment groups demon-
strated improvements over placebo across a broad range
of global disease activity measures. In the whole modified
ITT population, 25.5% of the placebo group achieved
SRI(4) response with sustained reduction of oral cor-
ticosteroids, compared with 51.5% in the anifrolumab
300-mg group (P, 0.001) and 38.5% in the anifrolumab
1,000-mg group (P5 0.048). Response rates in the IFN-
high population were 19.7% for placebo, 52.0% for the
anifrolumab 300-mg group (P, 0.001), and 38.5% for the
anifrolumab 1,000-mg group (P5 0.013). No differences
from placebo were seen in the patients with a low IFN
gene signature at screening (IFN-low subpopulation) at
week 24 or week 52 (Table 2 and Figure 1).
Consistent with the primary end point results, a
greater percentage of patients receiving anifrolumab met
criteria for SRI(4) response without the oral corticosteroid
taper requirement (Table 2 and Figure 1), and the modi-
fied SRI responses, requiring 5-, 6-, 7-, or 8-point reduc-
tions in SLEDAI-2K scores. Both anifrolumab dosages
were associated with higher rates of response in the
BICLA compared with placebo (Table 2, Figure 2, and
Supplementary Figure 3, available on the Arthritis & Rheu-
matology web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.39962/abstract). The differentiation between pla-
cebo and anifrolumab occurred within 6 months and was
Figure 1. Efficacy results at week 52 in patients with systemic lupus erythematosus (SLE) receiving anifrolumab 300 mg, anifrolumab 1,000 mg,
or placebo. Anifrolumab treatment led to a greater rate of response across multiple end points. The benefit observed in the overall modified
intent-to-treat population was driven by the patients with a high interferon (IFN) gene signature (IFN test high subpopulation), which represents
;75% of the entire cohort. The odds ratios (ORs), 90% confidence intervals (90% CIs), and P values are from a logistic regression model
adjusted for stratification factors. SRI(4)5 SLE Responder Index requiring a $4-point reduction in SLE Disease Activity Index 2000 (SLEDAI-
2K) score; OCS5 oral corticosteroid; BICLA5British Isles Lupus Assessment Group 2004–based Combined Lupus Assessment.
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maintained or increased through week 52 (Figure 2).
Improvements in physician’s global assessment at week 52
were also greater for the anifrolumab-treated groups than
for the placebo-treated group (Table 2), with a greater
effect observed in the 300-mg treatment group compared
with the 1,000-mg treatment group. For all outcomes, the
treatment effects observed in the overall population were
driven by the IFN-high subset (Table 2 and Figure 2).
The study also assessed various measures of low dis-
ease activity. A SLEDAI-2K score of #2 at week 52 was
achieved in 17.6% in the placebo group, 35.4% in the
anifrolumab 300-mg group (P5 0.004 versus placebo), and
32.7% in the anifrolumab 1,000-mg group (P5 0.012 ver-
sus placebo) (see Supplementary Figure 4, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39962/abstract), and a score of 0
was achieved in 7.8% in the placebo group, 18.2% in the
anifrolumab 300-mg group (P5 0.033 versus placebo), and
19.2% in the anifrolumab 1,000-mg group (P5 0.018 ver-
sus placebo). Major clinical response, defined as a
BILAG 2004 score of C or better in all organ domains
at week 24 with maintenance of this response through
week 52, was achieved in 6.9%, 19.2% (P5 0.012), and
17.3% (P5 0.025) in the placebo, anifrolumab 300-mg,
and anifrolumab 1,000-mg groups, respectively (Table 2
and Supplementary Figure 4).
The numbers of patients who developed new
BILAG 1A or 2B flares at any time during the study
were reduced by 28% and 29%, and the numbers who
developed new BILAG A flares were reduced by 46%
and 35%, in the anifrolumab 300-mg and anifrolumab
1,000-mg groups, respectively (Table 2).
A reduction in background oral corticosteroid dos-
age to#7.5 mg/day at week 52 in those taking$10 mg/day
at baseline was achieved in 56.4% of the patients in the
anifrolumab 300-mg group (P5 0.001) and 31.7% of the
patients in the anifrolumab 1,000-mg group (P5 0.595),
compared with 26.6% of the patients receiving placebo.
Anifrolumab-treated patients demonstrated greater
improvements than those receiving placebo across a range
of organ-specific disease measures and patient-reported
outcomes. The percentage of patients with a baseline
CLASI activity score of $10 who had a $50% reduction
in this score by week 52 was greater for both anifrolumab
dosages (63.0% for 300 mg [P5 0.013] and 58.3% for
1,000 mg [P5 0.077]) compared with placebo (30.8%)
(Table 2 and Figure 3). Improvement in arthritis was also
greater in patients receiving anifrolumab (Figure 3 and
Supplementary Figure 4). In patients with $8 swollen
and $8 tender joints at baseline, a $50% decrease in
both the swollen and tender joint count was achieved in
a greater percentage of anifrolumab-treated patients
Figure 2. Efficacy results over time in patients with systemic lupus erythematosus (SLE) receiving anifrolumab 300 mg, anifrolumab 1,000 mg,
or placebo. Treatment was given every 4 weeks from week 1 to week 48. A, Proportion of patients achieving an SLE Responder Index response
over time in the modified intent-to-treat (ITT) population and in the interferon (IFN)–high and IFN-low subsets. B, Proportion of patients
achieving a British Isles Lupus Assessment Group 2004–based Combined Lupus Assessment response over time in the modified ITT population
and in the IFN-high and IFN-low subsets.
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than placebo-treated patients (48.6% for placebo, 69.6%
for anifrolumab 300 mg [P5 0.038], and 64.6% for
anifrolumab 1,000 mg [P5 0.156]). Compared with pla-
cebo, greater proportions of patients in the anifrolumab
300-mg group achieved a .3-point improvement in the
FACIT-F scale, a$3.1-point improvement in the physical
component summary score of the SF-36 health survey,
and a $3.8-point improvement in the mental component
summary score of the SF-36 health survey. However,
none of these comparisons achieved statistical significance
(Table 2).
Assessments of biologic parameters were under-
taken to investigate response following administration
of anifrolumab. In patients with anti-dsDNA antibodies
detectable by the AtheNA Multi-Lyte ANA-II Plus
assay at baseline, a numerically greater decrease in anti-
dsDNA antibodies was observed with anifrolumab than
with placebo (mean6SD 224.46 177.6 for placebo,
270.36 166.9 for anifrolumab 300 mg [P5 0.067], and
243.86 86.3 for anifrolumab 1,000 mg [P5 0.144]).
Similarly, in patients with low complement C3 concen-
trations at baseline, a nonsignificant numerically greater
increase in complement C3 concentrations was observed at
week 52 in patients treated with anifrolumab compared
with those treated with placebo (mean6 SD 7.76 18.9 for
placebo, 12.96 19.1 for anifrolumab 300 mg [P5 0.277],
and 12.06 16.5 for anifrolumab 1,000 mg [P5 0.242]) (see
Supplementary Figure 6, available on the Arthritis & Rheu-
matology web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.39962/abstract). No effect on complement C4 was
observed. The median neutralization ratios of a 21-
gene type I IFN signature in the IFN-high subpopula-
tion at week 24 were 89.7 and 91.7 for the anifrolumab
300-mg and anifrolumab 1,000-mg groups, respec-
tively. This degree of suppression was maintained until
week 52. No neutralization in gene expression was
observed with placebo. The rates of antidrug anti-
bodies at any time postbaseline were low, with no
difference between treatment groups (3% for placebo,
5.1% for anifrolumab 300 mg, and 2.0% for
anifrolumab 1,000 mg).
Safety. The safety population consisted of the
305 patients who received at least 1 dose of study drug.
One patient randomized to the placebo group
Figure 3. Organ-specific efficacy results over time in patients with systemic lupus erythematosus (SLE) receiving anifrolumab 300 mg,
anifrolumab 1,000 mg, or placebo. Treatment was given every 4 weeks from week 1 to week 48. A, Left, Proportion of patients with a Cutaneous
Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score of $10 at baseline (n5 77) who had $50% improvement in the
CLASI score. Right, A representative example of skin response following anifrolumab treatment. B, Left, Proportion of patients with $8 swollen
and $8 tender joints at baseline (n5 37 in the placebo group, n5 46 in the anifrolumab 300-mg group, and n5 48 in the anifrolumab 1,000-mg
group) who had $50% improvement in the swollen and tender joint count. Right, Mean6 SEM change from baseline in the active joint count
in the modified intent-to-treat population. Joint counts are based on the assessment of 28 joints.
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mistakenly received a single dose of anifrolumab
(1,000 mg). This patient was included in the 1,000-mg
anifrolumab group for the safety analyses. The percent-
ages of patients with at least 1 adverse event (77.2% in the
placebo group, 84.8% in the anifrolumab 300-mg group,
and 85.7% in the anifrolumab 1,000-mg group) and seri-
ous adverse events (18.8% in the placebo group, 16.2% in
the anifrolumab 300-mg group, and 17.1% in the
anifrolumab 1,000-mg group) were similar across all treat-
ment groups. Adverse events led to treatment discontinua-
tion in 7.9% of the patients receiving placebo and 3.0%
and 9.5% of the patients receiving anifrolumab 300 mg
and anifrolumab 1,000 mg, respectively. The most fre-
quently reported adverse events were headache, upper
respiratory tract infection, nasopharyngitis, and urinary
tract infection (Table 3). There was 1 death (due to sepsis
syndrome) prior to randomization, and 1 death during the
study in a patient who received 1 dose of anifrolumab
1,000 mg. The patient had acute colitis with a rapidly
deteriorating clinical course and had features of macro-
phage activation syndrome prior to death. No infectious
agent was identified. Autopsy confirmed the cause of
death to be acute colitis and revealed portal vein throm-
bosis and increased numbers of phagocytic macrophages
in the bone marrow, consistent with macrophage
activation syndrome. This was not considered related to
the study drug by the investigator.
Herpes zoster infections were reported in 5.1%
and 9.5% of the patients in the anifrolumab 300-mg and
1,000-mg groups, respectively, compared with 2.0% in
the placebo group. All patients responded promptly to
antiviral treatment. One patient in the 300-mg group
discontinued treatment due to transverse myelitis with a
positive PCR test for herpes zoster in the cerebrospinal
fluid; the patient responded to antiviral and high-dose
corticosteroid treatment. The percentages of patients
who were reported as developing influenza were greater
in the anifrolumab 300-mg group (6.1%) and anifrolumab
1,000-mg group (7.6%) than in the placebo group (2.0%).
Infusion-related reactions were reported in 6 (5.9%), 2
(2.0%), and 4 (3.8%) of the patients in the placebo,
anifrolumab 300-mg, and anifrolumab 1,000-mg groups,
respectively. Upper respiratory infections (reported under
various terms) occurred more frequently in patients
treated with anifrolumab (36.4% in the anifrolumab 300-
mg group and 41.9% in the anifrolumab 1,000-mg group)
compared with placebo (28.7%). No clinically important
worsening was observed in hematology or chemistry pan-
els, urinalysis, vital signs, lipid parameters, or electro-
cardiograms in any of the treatment groups.
Table 3. Adverse events (safety population)*
Placebo
(n5 101)
Anifrolumab
300 mg (n5 99)
Anifrolumab
1,000 mg (n5 105)
Both anifrolumab
doses (n5 204)
Any adverse event 78 (77.2) 84 (84.8) 90 (85.7) 174 (85.3)
Serious adverse events 19 (18.8) 16 (16.2) 18 (17.1) 34 (16.7)
Death 0 (0.0) 0 (0.0) 1 (1.0) 1 (0.5)
Adverse events leading to
discontinuation
8 (7.9) 3 (3.0) 10 (9.5) 13 (6.4)
Treatment-related adverse
events leading to
discontinuation
2 (2.0) 1 (1.0) 4 (3.8) 5 (2.5)
Adverse events of special
interest†
12 (11.9) 10 (10.1) 15 (14.3) 25 (12.3)
Most common adverse events‡
Headache 13 (12.9) 12 (12.1) 12 (11.4) 24 (11.8)
Upper respiratory tract
infection
10 (9.9) 13 (13.1) 11 (10.5) 24 (11.8)
Nasopharyngitis 4 (4.0) 12 (12.1) 12 (11.4) 24 (11.8)
Urinary tract infection 11 (10.9) 15 (15.2) 7 (6.7) 22 (10.8)
Bronchitis 4 (4.0) 7 (7.1) 9 (8.6) 16 (7.8)
Herpes zoster 2 (2.0) 5 (5.1)§ 10 (9.5) 15 (7.4)
Influenza 2 (2.0) 6 (6.1) 8 (7.6) 14 (6.9)
Diarrhea 4 (4.0) 4 (4.0) 8 (7.6) 12 (5.9)
Sinusitis 3 (3.0) 6 (6.1) 6 (5.7) 12 (5.9)
Cough 2 (2.0) 3 (3.0) 8 (7.6) 11 (5.4)
* Values are the number (%). Treatment was given every 4 weeks from week 1 to week 48.
† New or reactivated tuberculosis infection, herpes zoster infection, malignancy, or reactions associated
with infusion, hypersensitivity, or anaphylaxis.
‡ Adverse events (preferred term) reported by .5% of patients in the total (both doses) anifrolumab
group.
§ One patient also had transverse myelitis with a quantitatively positive test result for varicella-zoster
virus in the cerebrospinal fluid.
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DISCUSSION
The primary and secondary end points of this
study were met. Furthermore, compared with placebo,
anifrolumab treatment resulted in significantly greater
rates of improvement across a broad range of composite
and organ-specific disease activity measures as well as in
the achievement and maintenance of low disease activ-
ity, corticosteroid tapering (in the 300-mg group), and a
trend toward flare rate reduction. These results provide
compelling evidence that blocking IFNAR is a promis-
ing strategy in the treatment of SLE.
The analysis of the primary end point in 2 popu-
lations (the modified ITT population and a modified
ITT subpopulation of patients with a high IFN gene sig-
nature at screening) was based on the mechanism of
action of anifrolumab and the assumption that demon-
strating statistically significant benefit in the primary
end point at a 2-sided alpha level of 0.1 in either of the
populations would provide sufficient preliminary evi-
dence of efficacy to continue phase III studies in the
appropriate population. A 2-sided alpha level of 0.1 rep-
resents a 5% chance of declaring a positive study result
when there is no treatment effect (risk of proceeding with
an ineffective drug). The present study had a power of
88%, representing a 12% chance of declaring a negative
study result when there was a positive treatment effect
(risk of discontinuing development of a potentially effica-
cious drug). This combination of statistical risks was cho-
sen to balance the continuation and discontinuation risks
while maintaining a feasible phase IIb study. Further, to
keep the sample size within reasonable limits, no adjust-
ment was made for the multiplicity of testing the primary
end point in the 2 populations. Therefore, the results of
this study are clinically relevant, but are not definitive
until prospectively replicated in larger studies with a more
stringent alpha level and a more robust control for
multiplicity.
The anifrolumab dosages were selected based on
pharmacokinetic and pharmacodynamic modeling and
simulation from a previous study (18,19). Both the 300-
mg and 1,000-mg dosages were more efficacious than pla-
cebo, with the lower dosage showing greater numerical
response rates at week 52 for many end points (Table 2).
The fact that the degrees of IFN gene signature inhibition
were similar with the low and high anifrolumab dosages
supports a plateau effect rather than an inverse dosage
response. However, other mechanisms, such as an
increased response in inducible immunologic feedback
leading to a lower rate of response with the greater
anifrolumab dosage, cannot be excluded. Biomarker stud-
ies to address this question are currently underway.
The fact that greater efficacy was seen in all end
points in patients with high baseline IFN gene signa-
tures compared with those with low baseline IFN gene
signatures supports the pathobiology of this treatment
strategy. The lack of treatment effect in the IFN-low sub-
group was due to a greater response to placebo and stan-
dard therapy and not to a lower response to anifrolumab,
suggesting that the IFN-high subgroup represents a sub-
population more likely to benefit from the addition of
anifrolumab to standard therapy. The interpretation of the
results in the IFN-low subgroup is limited by its small size,
and thus larger studies are needed to fully evaluate the
effect of anifrolumab in this population.
Anifrolumab treatment was well tolerated, and
adverse events reported were similar across the 3 treat-
ment groups. Consistent with the mechanism of action
of anifrolumab, a dosage-related increase was observed
in the occurrence of upper respiratory infections and
reactivation of herpes zoster. Importantly, responses to
antiviral treatment were prompt in the herpes zoster
cases. In addition, there were more cases reported as
influenza in patients treated with anifrolumab; however,
most of these cases were not confirmed by laboratory
testing or the application of strict clinical criteria. To
accurately assess the true risk of influenza, future stud-
ies should require laboratory confirmation of influenza
infections. Ensuring that patients’ immunizations are up
to date prior to administration of anifrolumab may
decrease the risk of influenza and other infections. The
dosage-related increase in these infections, together
with the fact that increasing the dosage from 300 mg to
1,000 mg did not lead to an increase in efficacy, indi-
cates a more favorable risk–benefit profile for the 300-
mg dosage.
This is the most successful phase II study in SLE to
date. The benefits achieved across multiple global and
organ-specific disease activity measures compare favorably
to those observed in other recent studies of potential lupus
therapies (15,16,29,31). The phase IIb study evaluating
sifalimumab in a similar cohort of patients met its primary
and some of its secondary end points, albeit with smaller
treatment effects (16). The greater efficacy and broader
impact demonstrated by anifrolumab are likely the result
of achieving greater suppression of the type I IFN pathway.
The positive results of the present study suggest that target-
ing IFNAR is a promising and novel therapeutic approach
for patients with SLE whose disease does not respond to
currently available therapies.
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